Table 1.

Reduced B16F10 or 4T1 invasion after i.t. treatment of CD8⁺ T cell EVs

I.t. treatment	No. of mice with B16F10 invasion/total mice (%)	No. of mice with 4T1 invasion/total mice (%)
Untreated	6/12 (50%)	2/4 (50%)
DUC18 CD8 EV	0/13 (0%)	1/5 (20%)
BALB TB CD8 EV	2/3 (66.7%)	n.t.
BALB CD8 EV	0/3 (0%)	n.t.
BALB CD4 EV	2/5 (40%)	3/5 (60%)

n.t. not tested

Number of B16F10- or 4T1-bearing mice with muscle and/or fatty layer invasion beyond the tumour tissues (impossible to remove the subcutaneous tumours surgically) was counted